Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a ...

Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, Ratings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leerink Partners analyst Thomas Smith has maintained their bullish stance on VRDN stock, giving a Buy rating on January 14.Invest with ...

VRDN Viridian Therapeutics Inc Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Veligrotug, ...

WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

The companies analyzed in the report include Horizon Therapeutics, Viridian Therapeutics, Viatris, Sanofi Novartis, Bayer AG, Teva Pharmaceuticals, F. Hoffmann-La Roche AG, AbbVie, and GSK plc.

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...